About the Company
Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NKTR News
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata.
Biotech naming trends bypass 'buzzwords and business speak' to build whimsical, memorable brands
In a world overrun by innovative biotechs, be a Mammoth Biosciences. Or a Nutcracker Therapeutics. Or Viking Therapeutics or ...
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 90+ companies and 110+ ...
US open: Stocks higher following retail sales
Wall Street stocks were in the green early on Monday as retail sales boosted sentiment and market participants prepared for ...
Where Do Analysts See Nektar Therapeutics (NASDAQ: NKTR) Heading?
The trading price of Nektar Therapeutics (NASDAQ:NKTR) closed lower on Monday, April 01, closing at $0.90, -3.22% lower than its previous close. In examining the 52-week price action we see that the ...
US close: Stocks finished mixed after Powell urges patience on rate cuts
US stocks finished mixed on Tuesday after bond yields climbed on the back of comments from Federal Reserve chair Jerome ...
Stocks are headed for a decade-long 'dead' zone with losses on par with the dot-com bust, fund manager says
That "dead ball" period will last for at least the next decade, Smead said, and it will only end once all the enthusiasm for ...
Nektar Network Unveiled to Elevate Ethereum’s Trust Layer and Combat Centralization
Chainwire Nektar Network – the multilayered Re-staking network is designed to optimize Ethereum’s security model … Continue ...
Loading the latest forecasts...